TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00258479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModafinilNicotine Replacement Therapy
Description: A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ModafinilNicotine Replacement Therapy
Description: A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: See Modafinil Intervention Description above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: See Modafinil Intervention Description above.
Study: NCT04028492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Tradipitant
Description: BID
Study: NCT01546571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: POL-103A
Description: POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: POL-103A without API
Description: Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
Study: NCT01040663

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention
Description: Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention
Description: Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intervention
Description: Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
Study: NCT03034382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 0.5%
Description: 10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
Study: NCT03411811

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
Study: NCT04038476

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard monitoring + transcutaneous CO2 monitoring
Description: The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Standard monitoring
Description: The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
Study: NCT04401722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PANCREATICODUDENECTOMY
Description: dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PANCREATICODUDENECTOMY
Description: dissection and removal of periampulary tumour with 3 reconstruction PJ, HJ, and GJ
Study: NCT00836069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No drug name provided by Sponsor; drug referenced as PD 0332334
Description: Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No drug name provided by Sponsor; drug referenced as PD 0332334
Description: Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive substance, oral tablet, once per day, for 10 weeks.
Study: NCT03739411

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Carbon C 13 Pyruvate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy for cancer outside of this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Undergo chemotherapy for cancer outside of this study.
Study: NCT00898274

Intervention type: OTHER
Intervention: immunoenzyme technique
Description: Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.

Intervention type: OTHER
Intervention: immunoenzyme technique
Description: Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances \[TBARS\] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
Study: NCT01141140

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy
Description: Favourable nutritional characteristics.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet
Description: Benefits of an ingredient/nutrient for weight management

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.
Study: NCT04107779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS
Description: JUUL 5%, ENDS for 6-days in confinement
Study: NCT01141140

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unhealthy
Description: Hedonic characteristics and less healthy ingredients.
Study: NCT04107779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS
Description: JUUL 3%, ENDS for 6-days in confinement
Study: NCT00196170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RF ablation of the cavo-tricuspid isthmus
Description: 8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryo ablation of the cavo-tricuspid isthmus
Description: Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus
Description: irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryo 6.5mm tip ablation of the cavotricuspid isthmus
Description: cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
Study: NCT02727621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
Study: NCT02058914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fructose sweetened beverage
Description: 710 ml per day of a HF-sweetened beverage
Study: NCT04107779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS
Description: JUUL 5%, ENDS for 6-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS
Description: JUUL 3%, ENDS for 6-days in confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette
Description: Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement

Intervention type: OTHER
Group type: OTHER
Intervention: Tobacco/Nicotine Abstention
Description: No smoking for 6-days in confinement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand of cigarettes
Description: Continue smoking UB for 6-days in confinement.
Study: NCT01904565

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperthermia and Proton Beam
Description: 1. Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~2. Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose.
Study: NCT04005092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hCPAP versus HFNC
Description: The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hCPAP versus HFNC
Description: The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
Study: NCT01658852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04022434

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placedo
Description: Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alanine
Description: Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
Study: NCT04498312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave
Description: The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave
Description: The participant was placed into supine lying position then the head of the shock wave was applied on the anterior or posterior aspect of the thigh which was scanned with 2000 shots for both horizontal direction and vertical direction. The period of each session was 15 minutes, 2 times/week for 4 weeks
Study: NCT04278924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 SC injection.
Study: NCT01928615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab - subcutaneous solution
Description: Trastuzumab was supplied as a solution for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy for early breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard chemotherapy for early breast cancer.
Study: NCT01500005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baby D3 drops
Description: 2000-4000 iu per day
Study: NCT02230176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA0-Tyr3-Octreotate
Study: NCT01974362

Intervention type: DEVICE
Intervention: Dental Implant
Description: Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications

Intervention type: DEVICE
Intervention: Dental Implant
Description: Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications

Intervention type: DEVICE
Intervention: Dental Implant
Description: Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications

Intervention type: DEVICE
Intervention: Monolithic Zirconia (MZ)
Description: rehabilitation with monolithic zirconia implant-prosthesis with bucal feldspathic veneer

Intervention type: DEVICE
Intervention: Zirconia-Feldspathic (PVZ)
Description: restore dental implants with a zirconia suprastructure and feldspathic veneers

Intervention type: DEVICE
Intervention: Monolithic Zirconia (FCMZ)
Description: Full contour full arch zirconia rehabilitation
Study: NCT03452150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0316
Description: If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined